GlassScriptPhysician profile
John S Wisniewski
NPI 1689786568
$3,208.36
in general payments reported to CMS, 2019-2025
17 companies · $89.31 in 2025
The $89.31 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $473 · 2021: $561 · 2022: $932 · 2023: $526 · 2024: $98.47 · 2025: $89.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.23 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,152.00 | 2019-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $623.15 | 2019-2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $557.37 | 2021-2024 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $226.79 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $124.94 | 2022-2025 | |
| Lilly USA, LLC | $110.46 | 2020-2023 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $90.46 | 2020-2022 | |
| Abbott Laboratories | $83.57 | 2021-2023 | Freestyle Libre 3 |
| Lifescan, INC. | $58.20 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $52.25 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $33.73 | 2019-2020 | |
| Ibsa Pharma INC. | $20.58 | 2023 | Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $19.85 | 2020 | |
| Genentech USA, INC. | $17.80 | 2020 | |
| Daiichi Sankyo INC. | $13.86 | 2024 | Injectafer |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.00 | 2019 | |
| Horizon Therapeutics Plc | $11.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wisniewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.